← Leaderboards
Benjamin G Vincent
Univ Of North Carolina Chapel Hill
$6,541,786
Attributed
$8,211,637
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,211,637 · 5
By mechanism
R37$3,644,761 · 1
R01$2,937,565 · 1
P30$1,227,173 · 2
R21$402,138 · 1
Top collaborators
- William Y Kim7 shared
- Leon Garland Coleman2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Zibo Li$7,321,417
- Tracy L Rose$786,888
- Angela B Smith$499,624
- Madison Rose Glass$99,156
- Michael Sean Sturdivant$75,250
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneTumorResponseNeoantigensSamplingCellsT Cell ResponseImmunotherapyResistanceMalignant NeoplasmsT-LymphocyteImmune ResponseCd8-Positive T-LymphocytesGenetic SignatureCostIn VivoSingle-Cell Rna SequencingPhenotypeTechnologyData SetMass Spectrum AnalysisDoseAnti-Pd1 TherapyCancer Therapy
Grant awards (19)
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation.$1,055,300
R37 · FY2025 · CA · contact PI
Chemotherapy and the Bladder Cancer Immune Microenvironment$537,831
R01 · FY2024 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation$498,982
R37 · FY2024 · CA · contact PI
Immunogenics and Flow Cytometry$283,193
P30 · FY2024 · CA · contact PI
Chemotherapy and the Bladder Cancer Immune Microenvironment$82,863
R01 · FY2024 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment$554,816
R01 · FY2023 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation$514,741
R37 · FY2023 · CA · contact PI
Immunogenics and Flow Cytometry$314,660
P30 · FY2023 · CA · contact PI
In vivo Assessment of Chemotherapy Remodeling of the Bladder Cancer Immune Microenvironment$74,967
R01 · FY2023 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment$554,812
R01 · FY2022 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation$525,246
R37 · FY2022 · CA · contact PI
Immunogenics and Flow Cytometry$314,660
P30 · FY2022 · CA · contact PI
Ethanol Inhibition of anti-PD-1 Immunotherapy via T-cell Dysfunction and Intestinal Dysbiosis$184,656
R21 · FY2022 · AA
Chemotherapy and the Bladder Cancer Immune Microenvironment$566,138
R01 · FY2021 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation$525,246
R37 · FY2021 · CA · contact PI
Immunogenics and Flow Cytometry$314,660
P30 · FY2021 · CA · contact PI
Ethanol Inhibition of anti-PD-1 Immunotherapy via T-cell Dysfunction and Intestinal Dysbiosis$217,482
R21 · FY2021 · AA
Chemotherapy and the Bladder Cancer Immune Microenvironment$566,138
R01 · FY2020 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation$525,246
R37 · FY2020 · CA · contact PI